Article thumbnail

TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes

By Andreas Holstein, Michael Hahn, Antje Körner, Michael Stumvoll and Peter Kovacs
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies.
  2. (2006). Altshuler D: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
  3. (2006). Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes
  4. (2007). CN: TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia
  5. (2007). CN: Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes
  6. (2006). Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes
  7. (2007). Froguel P: TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global metaanalysis. J Mol Med
  8. (2006). Froguel P: Transcription factor TCF7L2 genetic study in the French population - Expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes
  9. (2009). Gene association studies in acute lung injury: replication and future direction.
  10. (2007). McCarthy MI: TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia
  11. (2007). Ong KK, O’Rahilly S, Wareham NJ: TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British europid population. Diabetes
  12. (2007). P: TCF7L2 gene polymorphisms confer an increased risk for early impairment of glucose metabolism and increased height in obese children.
  13. (1999). RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA
  14. (2006). Shuldiner AR: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish - Replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes
  15. (2006). Stefansson K: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet
  16. (2001). Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mechanisms of Development
  17. (2009). The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res
  18. (2001). Utilization of oral hypoglycemic agents in a drug-insured US population. Diab Care
  19. (2007). Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia
  20. (2006). WT: Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes